Cellura is delighted to confirm its participation in Cell & Gene Therapy Europe 2025, one of the most influential global gatherings dedicated to the advancement, industrialization, and long-term impact of cellular, genetic, and regenerative therapies.
This major event brings together the full spectrum of the advanced therapies ecosystem, from early research and process development to CMC excellence, commercialization strategy, regulatory leadership, and industrial-scale manufacturing.
In a landscape where scientific discovery is rapidly converging with industrial reality, Cell & Gene Therapy Europe 2025 stands as a strategic nexus for the discussions, insights, and collaborations that will define the next decade of advanced therapeutics.
A Congress at the Crossroads of Science, Manufacturing, and Industrial Maturity
The field of cell and gene therapy is experiencing a pivotal shift. Early proof-of-concepts and clinical breakthroughs are giving way to a new, more complex era:
the era of scalable, controlled, patient-aligned cell manufacturing.
The industry now faces pressing questions:
- How do we scale fragile cell types without compromising their identity?
- How do we ensure reproducibility across sites, teams, and geographies?
- How do we reduce variability and build manufacturing systems that withstand regulatory and industrial scrutiny?
- How can next-generation tools support the transition from laboratory workflows to industrial-grade processes?
These questions are central to the program of Cell & Gene Therapy Europe and they align closely with the vision driving Cellura’s work.
A Strategic Presence Fully Aligned with Global Industry Priorities
Cellura’s participation is guided by a clear ambition: To support the sector in building predictable, robust, and scalable bioproduction frameworks capable of sustaining the therapies of tomorrow.
Throughout the congress, our team will take part in the key discussions shaping the future of the field, including:
- Scale-up and manufacturing innovation,
- CMC strategy and regulatory expectations,
- Quality, stability, and standardization in cell production,
- Process optimization for high-value, sensitive cell types,
- Industrial readiness and ecosystem integration,
- Automation, digitalization, and next-generation production models.
These conversations are increasingly vital as advanced therapies move from small-scale scientific achievements to globally deployed therapeutic solutions.
Cellura’s Perspective: Supporting High-Fidelity Cell Manufacturing
As a company focused on building stable, reliable, and gentle cell-culture environments, Cellura brings a perspective rooted in scientific precision, process understanding, and a strong commitment to the industrial readiness of advanced therapies. Our work is driven by the ambition to support scalable manufacturing models that preserve cell integrity while enabling consistent performance across development stages.
During the congress, Cellura will share insights on:
• the challenges faced by research and development teams when transitioning toward structured, scalable production frameworks,
• the growing need for homogeneous and tightly controlled culture environments for sensitive and high-value cell types,
• the operational and process bottlenecks commonly encountered when preparing for GMP-oriented workflows,
• the sector’s increasing demand for predictable, low-stress systems that reduce variability and enhance reproducibility.
Cellura’s technology, designed to maintain a gentle, uniform and controlled culture environment, will be presented within broader discussions on manufacturing innovation.
This contribution aims to support collective reflections on strengthening process robustness and establishing long-term reproducibility across advanced therapy production.
A Collaborative Approach to Industry Complexity
Cell & Gene Therapy Europe brings together a uniquely interdisciplinary audience: scientists, GMP specialists, engineers, regulatory decision-makers, operational directors, CDMOs, and technology developers.
For Cellura, the event is an opportunity to engage not only in scientific exchange but in strategic dialogue on how the sector can evolve toward:
- more controlled culture systems,
- more reliable scale-up pathways,
- better alignment between research practices and industrial requirements,
- and a stronger ecosystem supporting sensitive cell types with high therapeutic value.
During the event, our team will be available to:
- discuss operational and scientific challenges faced by therapy developers,
- explore collaborative opportunities with research institutions, clinical centers, and manufacturing partners,
- exchange perspectives on the future of standardized, low-stress culture environments,
- and support groups seeking greater reproducibility in early-stage experimentation and pre-GMP preparation.
Building the Foundations of Tomorrow’s Advanced Therapies
The promise of cell and gene therapy will only be fulfilled through robust, reproducible, and scalable cell manufacturing.
This requires tools, infrastructures, and collaborative networks capable of handling the intrinsic sensitivity of living systems with precision and control.Cellura enters Cell & Gene Therapy Europe 2025 with a long-term vision:
empowering the ecosystem to build manufacturing environments that are scientifically coherent, industrially viable, and aligned with the biological needs of the most delicate cells.As the sector continues to evolve, the convergence of process engineering, scientific excellence, and regulatory alignment will be crucial.
Cellura is committed to contributing to this transformation, thoughtfully, collaboratively, and with a deep understanding of the challenges ahead.We look forward to connecting with partners, exchanging with thought leaders, and contributing to the strategic discussions that will define the future of advanced therapies.
For further information or to arrange a meeting:
Email: contact@cellura.io
